Combinations of Bevacizumab and Erlotinib Show Activity in Colorectal Cancer Independent of RAS Status

MLA

Christophe Tournigand, et al. “Combinations of Bevacizumab and Erlotinib Show Activity in Colorectal Cancer Independent of RAS Status.” Clinical Cancer Research, vol. 24, May 2018, pp. 2548–58. EBSCOhost, https://doi.org/10.1158/1078-0432.ccr-17-3187.

APA

Christophe Tournigand, Ariel Savina, Aimery de Gramont, Anaïs Bouygues, Benoist Chibaudel, Nathalie Ferrand, Michèle Sabbah, Paul Mésange, Alexandre E. Escargueil, Annette K. Larsen, & Thierry André. (2018). Combinations of Bevacizumab and Erlotinib Show Activity in Colorectal Cancer Independent of RAS Status. Clinical Cancer Research, 24, 2548–2558. https://doi.org/10.1158/1078-0432.ccr-17-3187

Chicago

Christophe Tournigand, Ariel Savina, Aimery de Gramont, Anaïs Bouygues, Benoist Chibaudel, Nathalie Ferrand, Michèle Sabbah, et al. 2018. “Combinations of Bevacizumab and Erlotinib Show Activity in Colorectal Cancer Independent of RAS Status.” Clinical Cancer Research 24 (May): 2548–58. doi:10.1158/1078-0432.ccr-17-3187.